Xenex Disinfection Services, a San Antonio, TX-based provider of UV room disinfection systems for healthcare facilities, secured $11.3m in funding.
Backers included Battery Ventures, Targeted Technology Fund II and existing investors RK Ventures.
The company intends to use the funds for product development, international expansion, and increasing the company’s U.S. sales force.
Led by Morris Miller, CEO, and Mark Stibich, Chief Scientific Officer, Xenex provides a portable UV room disinfection system. It uses pulsed xenon ultraviolet light to destroy the viruses, bacteria, mold, fungus and bacterial spores in the patient environment that cause healthcare associated infections (HAI).
Its intense, broad-spectrum light penetrates the pathogens’ cell walls, causing the DNA to fuse instantly, rendering them unable to reproduce or mutate. With a five minute disinfection cycle, the device disinfects dozens of rooms per day, including patient rooms, operating rooms (ORs), equipment rooms, emergency rooms, intensive care units (ICUs) and public areas.
The Xenex device, which contains no mercury or hydrogen peroxide, is in use at nearly 200 hospitals and Veterans Affairs (VA) facilities in the U.S.